NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Going Public When You Can in Biotechnology

Michael R. Darby, Lynne G. Zucker

NBER Working Paper No. 8954
Issued in May 2002
NBER Program(s):   CF   PR

Scientist-entrepreneurs prominent in biotech and other high-technology industries view going public not as a cost-effective source of capital but as a cross between selling a now-proven innovation and winning a lottery. Unlike most empirical IPO analyses confined to those firms that go public, we study substantially all the non-public biotech firms founded up through 1989. The probability that one of these firms goes public in any given year increases with the quality of the firm's science base (use of recombinant DNA technology, number of articles by star scientists as or with firm employees, number of biotech patents), the percentage of eligible firms going public the year the firm was founded as a strategy indicator, recent biotech returns as an indicator of a hot market, and whether or how many rounds of venture capital has been obtained. The same key factors increase the expected proceeds raised from IPOs, but the quality of the firm's science base plays a more dominant role. All firms going public try to look like the next Genentech, but only those with the strong science base necessary for success attract large investments.

download in pdf format
   (159 K)

email paper

This paper is available as PDF (159 K) or via email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w8954

Published: Michael R. Darby and Lynne G. Zucker, “Real Effects of Knowledge Capital on Going Public and Market Valuation,” in Naomi Lamoreaux and Kenneth Sokoloff, eds., Financing Innovation in the United States, 1870 to the Present, Cambridge, MA: The MIT Press, 2007. [ISBN 0-262-12289-8, pp. 433-467]

Users who downloaded this paper also downloaded these:
Zucker, Darby, and Armstrong w8499 Commercializing Knowledge: University Science, Knowledge Capture, and Firm Performance in Biotechnology
Zucker, Darby, and Brewer w4653 Intellectual Capital and the Birth of U.S. Biotechnology Enterprises
Zucker and Darby w6360 Capturing Technological Opportunity via Japan's Star Scientists: Evidence from Japanese Firms' Biotech Patents and Products
Darby and Zucker w9825 Grilichesian Breakthroughs: Inventions of Methods of Inventing and Firm Entry in Nanotechnology
Danzon, Nicholson, and Pereira w9615 Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us